Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 411
- Registration Number
- NCT00256178
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- Drug: Dexlansoprazole MRDrug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00255151
Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- Drug: Dexlansoprazole MRDrug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00255164
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 591
- Registration Number
- NCT00255190
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Lapaquistat acetate and lipid-lowering therapyDrug: Lipid-lowering therapy
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 400
- Registration Number
- NCT00251680
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2038
- Registration Number
- NCT00251693
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Dexlansoprazole MRDrug: Placebo
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 908
- Registration Number
- NCT00251745
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: PlaceboDrug: Dexlansoprazole MR
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 908
- Registration Number
- NCT00251758
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, PepticEsophagitis, Reflux
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2054
- Registration Number
- NCT00251719
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
Phase 3
Terminated
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Lapaquistat acetate and stable statin therapyDrug: Stable statin therapy
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 649
- Registration Number
- NCT00249899
© Copyright 2025. All Rights Reserved by MedPath